Introduction: Hiroshima University, in collaboration with BeRISE Corp, developed a virtual reality-based objective structured clinical examination (VR OSCE TM ) practice software, as an educational tool to enhance clinical skills. This study aimed to assess the effectiveness of training with VR OSCE TM for medical students. Methods: Twenty medical students participated in this prospective, pre- and post-intervention study. They conducted medical interviews and physical examinations of simulated patients using VR OSCE TM and presented their findings. Two instructing doctors assessed and scored their performance based on predefined criteria before and after training. A paired t-test was used to analyze the pre- and post-training scores of five parameters: (a) safety checks, (b) patient care, (c) medical interviews and physical examinations, (d) presentation skills, and (e) overall performance. A questionnaire survey was also administered to assess participants’ perceptions of VR OSCE TM . Results: Post-training scores significantly improved across all parameters compared with pre-training scores ( p < 0.01). Scores for (a) safety checks (Pre: 6.0 ± 1.9, Post: 8.6 ± 1.8) and (b) patient care (Pre: 4.6 ± 1.8, Post: 7.8 ± 1.1) were close to the OSCE passing threshold prior to training. Notably, there were remarkable improvements in scores for (c) medical interviews and physical examinations (Pre: 4.1 ± 1.7, Post: 7.3 ± 1.2) and (d) presentation skills (Pre: 3.5 ± 1.3, Post: 7.0 ± 1.6). Scores for (e) overall performance (Pre: 3.8 ± 1.3, Post: 7.2 ± 1.5) mirrored these improvements. The survey indicated that all participants recognized the effectiveness of training with VR OSCE TM as a component of OSCE certification preparation. Conclusion: This study is the first to evaluate the educational impact of VR OSCE™ training in medical students. VR-based training appears to be effective, likely due to its immersive nature. These findings suggest that VR-based digital simulation has substantial potential to enhance medical education.
Background: Digital polymerase chain reaction (dPCR) is a highly sensitive molecular method that allows rapid detection of bacterial DNA and resistance genes, requiring only a small blood volume. Although not a new technology, its application in pediatric patients with suspected catheter-related bloodstream infection (CRBSI) remains limited. Case presentation: A 16-year-old female, diagnosed with recurrent acute myelogenous leukemia, received re-induction chemotherapy through a peripherally inserted central venous catheter (PICC). The patient developed a fever, and the blood culture (BC) drawn from the PICC was positive for methicillin-resistant S. epidermidis, leading to suspicion of CRBSI. Several antibiotics were used, and the PICC was replaced. Eventually, the fever subsided, and the BC was negative after PICC removal. The levels of S. epidermidis-specific DNA sequences and mecA genes were correlated with the results of the BC and clinical course. Turnaround time was significantly shorter in dPCR (3.5 h) than in the BC (14–21 h); dPCR was performed using only 400 µL of blood. Conclusions: This case highlights the potential of dPCR as a complementary tool to conventional BCs in the management of pediatric CRBSI. dPCR may support rapid decision-making and monitoring of the treatment response, particularly when sample volumes are limited.
Precision oncology, based on the genomic profile of tumors, is increasing in cancer treatment. It is important in pediatric and adolescent and young adult (AYA) malignancies, a group of rare cancers that are difficult to diagnose and progress quickly. We evaluated the usefulness of in‐hospital molecular profiling using a specific sequencing panel for pediatric and AYA malignancies in clarifying the diagnosis, predicting the prognosis, and identifying therapeutic targets. We evaluated the Oncomine Childhood Cancer Research Assay (203 genes, 1700 fusions) and analyzed 153 samples at diagnosis and 34 samples at relapse or refractory from 165 pediatric and AYA patients with various solid malignancies, including neuroblastoma, hepatoblastoma, brain tumor, and sarcoma. We simulated in‐hospital molecular profiling. In total, 320 reportable variants were identified in 153 samples (81.8%). Variants with clinical significance were identified in 62 samples (33.1%), including diagnostic variants in 26 (13.9%), prognostic variants in 17 (9%), targetable variants in 41 (21.9%), and variants with drug resistance in 18 (9.6%). Additionally, 62.0% and 94.1% of identified diagnostic and prognostic variants, respectively, had high levels of evidence. In five patients with cancer predisposition syndromes, all pathogenic germline mutations were validated. The turnaround time (TAT) from sample collection to reporting of the molecular profile was within seven working days. In‐hospital molecular profiling using a sequencing panel specified tailored for pediatric and AYA malignancies has a high rate of identifying reportable variants and enables accurate diagnosis, malignancy grading, and treatment selection, as well as cancer predisposition syndromes with a short TAT.